Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Since we began operations in November 2014, we have built a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock03/12/18
Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock03/08/18
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock03/07/18
There are currently no events scheduled.